U.S. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a cr

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10723405	
Filing Date		2003-11-25	
First Named Inventor Frank		k William Brice, Jr.	
Art Unit Examiner Name NYA		2182	
Attorney Docket Number		POU920030188US1	

				U.S.	PATENTS	Remove			
Examiner Initial*	r Cite No Patent Number Kind Code ¹ Iss		Issue Date	ue Date Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	6598144		2003-07-15	Bailey et al.				
	2	6742075		2004-05-25	Bailey et al.				
	3	7003586		2006-02-21	Bailey et al.				
If you wis	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.		Add		
			U.S.P	ATENT APPLI	ICATION PUBLICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevan	
	1	20020165897		2002-11-07	Kagan et al.				
	2	20030188062		2003-10-02	Luse et al.				
	3	20040030854		2004-02-12	Qureshi et al.				
					n information please click the Ad-		Add		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10723405	
iling Date		2003-11-25	
First Named Inventor Frank		William Brice, Jr.	
Art Unit		2182	
Examiner Name NYA			
Attorney Docket Number		POU920030188US1	

Examiner Initial*	Cite No	Foreigr Numbe	Document	Country Code ² j	Kind Code ⁴	Publication Date	Name of Par Applicant of Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	Ts
	1									
If you wish	h to a	dd additi	onal Foreign I	Patent Docume	nt citation	information p	lease click the	Add buttor	Add	
				NON-PAT	ENT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No							Ţŝ		
	1									
If you wis	h to a	dd additi	onal non-pate	nt literature doc	ument cit	tation informat	ion please clic	k the Add I	outton Add	
EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

See Knd. Octobe of USPTO Platein Documents at year, <u>USPTO, OCT</u> or MPEP 901.04. * Enter office in all issued the document, by the two-letter code (WIPO Standard STA). * Enter planese patient connectine, the analysis of the page of the ringer or the Engener purpose of the senior in Labor the patient document. *
**(And of document by the appropriate symbol as andicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if the propriate injuries of the propriate symbol as an experiment of the page of the page

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10723405	
Filing Date		2003-11-25	
First Named Inventor Frank		William Brice, Jr.	
Art Unit		2182	
Examiner Name NYA			
Attorney Docket Number		POU920030188US1	

CERTIFICATION STATEMENT

Please see 37 CF	R 1.97 ar	d 1.98 to make	the appropriate	selection(s):
------------------	-----------	----------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a deepin patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Sean F. Sullivan/	Date (YYYY-MM-DD)	2006-04-17
Name/Print	Sean F. Sullivan	Registration Number	38328

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take it hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. 0. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.